Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

Presentation ACC 2026

Essence-TIMI 73b CCTA Trial: Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis

Presenter: Nicholas Marston

March 30, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

Presentation ACC 2026

Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease: The Ez-PAVE randomized clinical trial

Presenter: Byeong-Keuk Kim

March 28, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

Presentation ACC 2024

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Presenter: Brian Bergmark

April 07, 2024

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Shelley Wood

March 08, 2023

Presentation ACC 2023

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Presenter: Annapoorna S. Kini

March 06, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

Presentation ACC 2022

The PACMAN AMI Randomized Clinical Trial

Presenter: Lorenz Räber

April 04, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

Advertisement

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Essence-TIMI 73b CCTA Trial: Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease: The Ez-PAVE randomized clinical trial

What’s Going to Be Hot at ACC 2026

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Need a Statin for Primary Prevention? There’s an App for That

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

The PACMAN AMI Randomized Clinical Trial

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content